Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Submitted by admin on September 5, 2023 - 8:39pm
Source: 
Motley Fool
News Tags: 
Novartis
biosimilars
Eylea
Headline: 
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
snippet: 
  • Novartis’ biosimilar candidate to Eylea has proven just as safe and effective.
  • The medicine could generate $500 million in annual sales for the Swiss drugmaker.
  • Income investors may find Novartis’ stock intriguing for this and other reasons.

Do Not Allow Advertisers to Use My Personal information